Capryol-Ethyl oleate self-microemulsifying system for improved intestinal absorption and hypoglycemic activity of empagliflozin

Key Points

• The research aims to evaluate the enhancement of intestinal absorption and hypoglycemic activity of empagliflozin using a self-microemulsifying drug delivery system (SMEDDS).
• The study employed a SMEDDS formulation of empagliflozin.
• Oral hypoglycemic activity was assessed by measuring the blood glucose reduction curve.
• Comparison was made between the SMEDDS and aqueous dispersion of empagliflozin.
• SMEDDS formulation resulted in a 1.45-fold increase in the area under the blood glucose reduction curve compared to the aqueous dispersion.
• Improved oral bioavailability of empagliflozin was observed with the SMEDDS formulation.